Skip to content
MarketScale
‹ Back to IndustriesSciences

DEERLAND TO PRESENT INITIAL RESULTS FROM CLINICAL TRIAL ON DE111® PROBIOTIC AT THE ISSN SPORTS NUTRITION CONFERENCE

Deerland will share results from their latest clinical study at the International Society of Sports Nutrition (ISSN) 15th Annual Conference and Expo, which is held from June 7 to 9, 2018 in Clearwater Beach, FL. Dr. Jeremy R. Townsend of Lipscomb University in Nashville, TN will present preliminary data on Deerland’s exclusive strain of Bacillus subtilis DE111…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share

Key takeaways

01

Deerland will share results from their latest clinical study at the International Society of Sports Nutrition (ISSN) 15th Annual Conference and Expo, which is held from June 7 to 9, 2018 in Clearwater Beach, FL.

02

Townsend of Lipscomb University in Nashville, TN will present preliminary data on Deerland’s exclusive strain of Bacillus subtilis DE111…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Deerland will share results from their latest clinical study at the International Society of Sports Nutrition (ISSN) 15th Annual Conference and Expo, which is held from June 7 to 9, 2018 in Clearwater Beach, FL. Dr. Jeremy R. Townsend of Lipscomb University in Nashville, TN will present preliminary data on Deerland’s exclusive strain of Bacillus subtilis DE111 titled “The Effect of Probiotic Supplementation on Markers of Immune and Endocrine Status in Division I Baseball Players.”

The purpose of the investigation was to study the effects of probiotic supplementation on potential immune and hormonal markers of overtraining and overreaching in team sport athletes. The double blind, placebo-controlled, randomized study involved 25 Division I male baseball athletes throughout their 12-week offseason training program. The results of this investigation showed TNF-α concentrations were significantly lower in the DE111 group. A trend for lower cortisol in the DE111 group was also observed compared to the placebo. These findings indicate that DE111 probiotic supplementation may reduce systemic low-grade inflammation.

ISSN conference participants can learn more about clinical studies like this one during the poster presentations from 12 to 2 pm on Saturday, June 9th. Learn more about Deerland’s product innovation at deerlandenzymes.com/products/.

About Deerland Enzymes and Probiotics

Deerland Enzymes & Probiotics, based in Kennesaw, Ga., specializes in customized enzyme and probiotic-based formulations, collaborating with customers to develop innovative and often proprietary solutions. In addition to customized formulations, the company offers a line of university and clinically studied branded products. Deerland provides regulatory support and also performs specialty contract manufacturing services, including bulk blends, liquids, hard shell capsules, and tablets; as well as bottling and labeling. To contact Deerland Enzymes & Probiotics, call 800.697.8179 or email info@DeerlandEnzymes.com.

About DE111® 

DE111 is a genome sequenced and clinically tested strain of Bacillus subtilis, a probiotic spore that supports digestive and immune health. The genome sequencing confirmed the strain contained no plasmids, antibiotic resistant or deleterious genes; the human clinical studies showed the strain’s ability to control microbial populations, aid in digestion and maintain general health. DE111 has the ability to form spores that protect the microbes from harsh conditions until they enter an environment ripe for germination, such as the GI tract. Because of this spore-forming ability, DE111 remains viable under a wide temperature and pH range, making it ideal for use in supplements as well as food and beverages.

Read more at deerlandenzymes.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Lab automation ROI hinges on integration, not instrument sensitivity claims

Lab automation ROI hinges on integration, not instrument sensitivity claims

At ADLM 2026, Waters and LabCollector delivered a clear message for lab leaders: the limiting factor in automation is often integration, not hardware. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer and is positioning it at “5x greater sensitivity” versus in-class instruments, according to SelectScience, but that advantage only carries through if sample prep, calibration and QA, middleware rules, and LIMS result review can keep pace. In parallel, LabCollector announced an AI Co-Scientist feature set for natural-language search, knowledge retrieval, and AI-assisted content creation inside ELN and LIMS workflows, also reported by SelectScience, shifting attention from pipetting speed to retrieval, approval, permissions, and versioning in systems that sit on the documentation path. The Scientist’s overview of semi-automated versus fully automated approaches reinforces the point: labs can automate in modules, but they have to run automation as one system.

  • 01The bottleneck in automation is often the handoff, instrument to middleware to LIMS, so sensitivity and throughput gains depend on interfaces and downstream review as much as the instrument spec.
  • 02Waters’ “5x greater sensitivity” positioning and LabCollector’s AI Co-Scientist both point to integration work, sample prep, calibration and QA, middleware rules, and LIMS result review, as the gating factor for ROI.
  • 03As ELN/LIMS add conversational search and AI-assisted content creation, speed gains move from pipetting to retrieval, approval, permissions, and versioning inside systems that sit in regulated or audited workflows.

Sep 3, 2026

AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission

AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission

AeroVironment’s MacCready Works has been contracted to build three autonomous Mars helicopters for NASA's SkyFall mission. This development highlights the company's capabilities in aerospace-grade autonomy and avionics integration. The project shows a strong connection between aerospace and defense industries in terms of supply chain management.

  • 01AeroVironment is co-designing and co-manufacturing three autonomous helicopters for NASA's SkyFall Mars mission with JPL.
  • 02SkyFall will use a 'SkyFall maneuver' where three helicopters are released from a carrier spacecraft, separate, deploy, descend, and land under their own power, avoiding a dedicated lander or host rover.
  • 03AeroVironment leads rotor systems, airframes, structures, avionics integration, and payload provisions, while JPL leads the power system, electronics, algorithms, and software.

Aug 29, 2026

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Pharmaceutical companies are increasingly using telehealth digital waiting rooms as prime advertising slots. These virtual spaces offer unique opportunities for pharma brands to engage patients before and after their virtual care visits. The trend is driven by fresh data on patient attention and strategic execution by agencies.

  • 01Pharmaceutical brands are using digital waiting rooms in telehealth platforms as premium ad slots.
  • 02New patient-attention data enhances pharma media plans for virtual care settings.
  • 03Virtual waiting rooms allow targeted patient engagement before and after healthcare consultations.

Aug 29, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512